Authors
Caihong Li, Andreas Baur, Lingfeng Pan
Published in
Progress in neuro-psychopharmacology & biological psychiatry. Pages 111799. Jun 23, 2026. Epub Jun 23, 2026.
Abstract
Parkinson's disease (PD) and cutaneous melanoma show epidemiological co-occurrence, but their shared genetic architecture remains unclear METHODS: We combined bidirectional time-dependent cox regression in the UK biobank (N ≈ 500,000) with a multi-layered genomic analysis using large-scale PD and melanoma GWAS summary statistics (N = 745,746). Genetic analyses included linkage disequilibrium score regression (LDSC), bidirectional Mendelian randomization (MR), PLACO, LAVA, and Bayesian colocalization RESULTS: Melanoma was associated with increased subsequent PD risk (HR = 1.62, 95% CI: 1.18-2.23), whereas the reverse PD-to-melanoma analysis was not statistically significant and was limited by low event counts. LDSC showed a modest positive genetic correlation (rg = 0.181, P = 0.04), while MR provided no evidence of bidirectional causality. PLACO identified 134 pleiotropic SNPs across 25 gene loci, including SOX6, the GDF5-GSS-EDEM2 cluster, and immune-related loci at 17q21.32. LAVA identified 17 locally correlated loci, with antagonistic effects predominating (11/17, 64.7%). Bayesian colocalization highlighted SOX6 as the strongest shared-signal locus (PP·H4 = 0.904; PP·H3 = 0.054) CONCLUSIONS: PD-melanoma co-occurrence is supported by shared but heterogeneous genetic architecture rather than bidirectional causality. Antagonistic local effects may partially offset genome-wide correlation, while SOX6 represents a prioritized colocalized candidate locus linking dopaminergic neuron vulnerability and melanocytic biology.
PMID:
42335983
Bibliographic data and abstract were imported from PubMed on 24 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 1
- Comments 0